DOCSLIB.ORG

Guidelines for Cryoprecipitate Transfusion

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Guidelines for Cryoprecipitate Transfusion Nadejda Droubatchevskaia, MD, Michelle P. Wong, MD, Kate M. Chipperfield, MD, FRCPC, Louis D. Wadsworth, MB, ChB, FRCPC, FRCPath, David J. Ferguson, MD, FRCPC Guidelines for cryoprecipitate transfusion A new document from the Transfusion Medicine Advisory Group describes appropriate use of cryoprecipitate plasma. ABSTRACT: The literature shows he Transfusion Medicine Ad - tologists and critical care physicians, there is often inappropriate use visory Group (TMAG) of BC and were subsequently approved by the of blood products, including cryo - T has prepared guidelines to pro- Transfusion Medicine Advisory Group precipitate plasma, because of in - vide physicians with current informa- (see Appendix B). adequate education of physicians. tion on the appropriate use of cryopre- Guidelines for cryoprecipitate trans- General considerations cipitate plasma. These guidelines are fusion have been developed by the available electronically on the British Physicians contemplating the use of Transfusion Medicine Advisory Group Table Columbia Provincial Coordinating cryoprecipitate (see ), should of British Columbia to educate clini- Office web site (www.blood keep in mind the following general cians and address transfusion prac- link.bc.ca) and will be updated period- considerations: tices in the province. These guide- ically. Prescribing physicians are • In British Columbia, informed con- lines are based on a MEDLINE responsible for referring to the most sent is required for the transfusion of search and consultation with hema- recent guidelines. cryoprecipitate. to pathologists and clinicians. At pre- • All routine coagulation parameters sent, transfusion of cryoprecipitate How the guidelines is indicated for hypofibrinogen emia/ were developed Dr Droubatchevskaia is a hema topatholo - dysfibrinogenemia, von Willebrand gist at St. Paul’s Hospital in Vancouver, These guidelines were developed to disease, hemophilia A, factor XIII British Columbia. Dr Wong is a hemato - direct therapy but are not intended as a deficiency, and management of pathology resident in the Department of rigid prescription for cryoprecipitate bleeding related to thrombolytic Pathology and Laboratory Medicine at the use. The guidelines are based on a therapy. Cryoprecipitate should not University of British Columbia. Dr Chip- MEDLINE search using the key be used to prepare fibrin glue or to perfield is regional medical leader, Blood words “cryoprecipitate” plus “trials” treat sepsis. Transfusion Medicine, Vancouver Coastal or “randomized” or “guidelines” or Health, and a clinical assistant professor in “reviews.” The levels of evidence and the Department of Pathology and Labora- grades of recommendations are based tory Medicine at UBC. Dr Wadsworth is a on standards developed by the US hematopathologist at Children’s and Wo - Agency for Healthcare Research and men’s Health Centre of BC, a clinical pro- Quality (formerly the US Agency for 1 fessor in the Department of Pathology and Health Care Policy and Research) (see Laboratory Medicine at UBC and is chair of Appendix A). Because of the limited the Transfusion Medicine Advisory Group number of clinical trials completed, of BC. Dr Fer guson is the medical director most of the recommendations are based of BC Bio medical Laboratories Ltd., and an on expert opinion—level IV evidence, assistant clinical professor in the Depart- grade C recommendation. These guide- ment of Path ology and Laboratory Medi- lines were reviewed by hematopathol- cine at UBC. ogists and clinicians, including hema- VOL. 49 NO. 8, OCTOBER 2007 BC MEDICAL JOURNAL 441 Guidelines for cryoprecipitate transfusion should be checked before ordering apy with either frozen plasma (FP) or py—see above) cryoprecipitate. This includes com- cryoprecipitate is usually indicated if Adult: 10 to 12 units (bags) every 12 plete blood count (CBC), platelet fibrinogen levels are less than 1.0 g/L, hours count, international normalized ratio and bleeding is present, although clin- Child: 1 unit (bag) per 6 kg of body (INR), partial thromboplastin time ically significant bleeding can occur at weight every 12 hours (PTT), and fibrinogen. higher levels. If fibrinogen levels are • Hemophilia A (only as a second-line • The Transfusion Medicine Laborato- greater than 1.0 g/L in the setting of therapy—see above) ry Service should be made aware of active bleeding secondary to DIC, then (Level IV evidence, grade C recom- the clinical diagnosis on the re quest FP should be given instead of cryo- mendation.) form used to order cryoprecipitate. precipitate in order to address the mul- F XIII deficiency. The reason for the transfusion should tiple factor deficiencies typical of Hereditary defi- also be clearly and accurately record- DIC. Cryo precipitate may be consid- ciency of factor XIII is an extremely ed in the patient’s chart, and in any ered as a substitute for FP when the rare condition. In 2006, the Canadian documentation that is used when required volume of plasma is relative- Hemophilia Registry (www.fhs.mc administering cryoprecipitate. ly contraindicated and targeted fibrino- master.ca/chr/2006) identified only 41 • Cryoprecipitate should be given only gen replacement in a small volume cases. Hemostasis may be achieved 2-4 after risks associated with transfu- is desirable. with levels as low as 2% to 3%. Com- sion of allogeneic blood products (Level IV evidence, grade C recom- pared with the half-life of other coag- have been considered and only when mendation.) ulation factors, the half-life of F XIII the benefits outweigh the risks. is very long (9 to 10 days). Plasma- von Willebrand (vWD) disease and • Alternative treatments or adjunctive derived F XIII concentrate (Fibro - hemophilia A (HA). agents should be used to minimize The current prac- gammin P) is licensed and available in or to avoid the use of cryoprecipi- tice in patients with mild (type 1) Canada through the Special Access tate. For example, desmopressin vWD disease or mild HA is to use Programme for use in patients with F (DDAVP), Humate P, fibrinogen desmopressin and/or antifibrinolytics XIII deficiency, but is not stocked in concentrates, and antifibrinolytic or virus-inactivated factor VIII (F VIII) all regional blood centres. Because of agents may be appropriate in specif- concentrate (e.g., Humate P), which the rarity of F XIII deficiency, specif- ic situations. contains both F VIII:C and von Wille- ic factor concentrate is usually not • Most laboratories in British Colum- brand factor multimers. Most hemo- readily available in emergent situa- bia convert the prothrombin time philia patients with F VIII:C deficien- tions, and it is in these situations that (PT) to the international normalized cy are treated with F VIII:C cryoprecipitate can and should be 7 ratio to facilitate comparison of re - concentrate, which is now a recombi- used. Dosing: sults between laboratories. (Through- nant product and no longer derived out the document, we have tried to from human plasma. Cryoprecipitate • 1 unit (bag) per 10 kg of body weight use the INR where possible, as this can be used by patients with vWD dis- every 7 to 14 days is typically what is reported by lab- ease that is unresponsive to desmo- (Level IV evidence, grade C recom- oratories.) pressin and by hemophilia A patients mendation.) in those locations where F VIII:C con- Clinical indications for use Management of bleeding related to centrates are not available. Every effort of cryoprecipitate thrombolytic therapy. must be made to obtain the preferred Cryoprecipi- Clinical experience supports the use recombinant factor concentrate for tate can be used to manage intracranial of cryoprecipitate in the following sit- hemophiliacs before resorting to the bleeding in patients during or after 2-6 uations. use of cryoprecipitate. administration of tissue plasminogen Hypodysfibrinogenemia. Dosing: 8 Reduc ed activator (tPA). Randomized con- levels of fibrinogen activity can result • vWD disease (as a second-line thera- trolled clinical trials of cyroprecipitate from either a functional or qualitative defect (dysfibrinogenemia) or a quanti- number of bags of = [(plasma volume in mL ϫ % increase in F VIII: C needed)/100] tative deficiency, as is seen in massive cryoprecipitate 80 transfusion or disseminated intravascu- lar coagulation (DIC). Trans fusion ther- 442 BC MEDICAL JOURNAL VOL. 49 NO. 8, OCTOBER 2007 Guidelines for cryoprecipitate transfusion Table. Characteristics of four frozen plasma products. Frozen plasma Fresh-frozen plasma Cryoprecipitate plasma Cryosupernatant plasma (from whole blood collection) (from apheresis collection) (cryo) (cryo-poor plasma) Whole blood is centrifuged at Whole blood is processed Plasma is frozen for 24 hours, Plasma is frozen for 24 hours, high speed, allowing separa- through a cell separator to and then thawed at 1°– 6°C and then thawed at 1°– 6°C tion of plasma, red blood cells obtain plasma. Plasma is until insoluble proteins precip- until insoluble proteins precip- (RBCs), and the buffy coat frozen within 8 hours of col- itate. The pack is centrifuged itate. The pack is centrifuged layer (platelets, white blood lection and is designated as to obtain the cryoprecipitate. to obtain the supernatant. cells, some RBCs and plasma). fresh-frozen plasma (FFP). In The cryoprecipitate is then The supernatant, or cryo-poor Plasma is frozen within 24 general, 1 unit of FFP from refrozen for storage. plasma, is then refrozen for hours of collection and is des- apheresis collection is equiva- storage. ignated as frozen
Load more

Recommended publications
  • Guidelines for Transfusions
    Guidelines for Transfu- sion Prepared by: Community Transfusion Committee Lincoln, Nebraska CHAIR: Aina Silenieks, MD MEMBERS: L. Bausch, M.D. R. Burton, M.D. S. Dunder, M.D. D. Voigt, M.D. B. J. Wilson, M.D. COMMUNITY Becky Croner REPRESENTATIVES: Ellen DiSalvo Christa Engel Phyllis Ericson Kelly Gillaspie Pat Gilles Vic Grdina Jessica Henrichs Kelly Jensen Laurel McReynolds Christina Nickel Angela Novotny Kelley Thiemann Janet Wachter Jodi Wikoff Guidelines For Transfusion Community Transfusion Committee INTRODUCTION The Community Transfusion Committee is a multidisciplinary group that meets to monitor blood utilization practices, establish guidelines for transfusion and discuss relevant transfusion related topics. It is comprised of physicians from local hospitals, invited guests, and community representatives from the hospitals’ transfusion services, nursing services, perfusion services, health information management, and the Nebraska Community Blood Bank. These Guidelines for Transfusion are reviewed and revised biannually by the Community Trans- fusion Committee to ensure that the industry’s most current practices are promoted. The Guidelines are the standard by which utilization practices are evaluated. They are also de- signed to provide helpful information to assist physicians to provide appropriate blood compo- nent therapy to patients. Appendices have been added for informational purposes and are not to be used as guidance for clinical decision making. ADULT RED CELLS A. Indications 1. One of the following a. Hypovolemia and hypoxia (signs/symptoms: syncope, dyspnea, postural hypoten- sion, tachycardia, angina, or TIA) secondary to surgery, trauma, GI tract bleeding, or intravascular hemolysis, OR b. Evidence of acute loss of 15% of total blood volume or >750 mL blood loss, OR c.
    [Show full text]
  • Requirements for Blood and Blood Components Intended for Transfusion Or for Further Manufacturing Use
    Requirements for Blood and Blood Components Intended for Transfusion or for Further Manufacturing Use Office of Blood Research and Review CBER, FDA Ask the FDA Session – AABB Annual Meeting October 26, 2015 1 Outline • Overview – Historical Background – Intent of the Rule – Organization of the Rule • Selected Provisions – Relevant Transfusion-Transmitted Infection – Control of Bacterial Contamination of Platelets – Medical Supervision – Donor Acknowledgement – Alternative Procedures – Donor Eligibility • Implementation 2 GAO Oversight and FDA Concerns • Publish in the form of regulations the guidelines that FDA deems essential to ensure the safety of the blood supply • Concern about the delay in requiring testing for emerging infectious agents, e.g. HTLV • Concern about blood safety and the regulations being out-of-date • Concerns about donor safety 3 Intent of the Final Rule • To better assure the safety of the blood supply and to help protect donor health • To make donor eligibility and testing requirements more consistent with current practices and to provide flexibility with regard to emerging infectious diseases • To accommodate technological advances • To establish requirements for donor education, donor history, and donor testing 4 Organization of the Final Rule - 1 • A. General • B. Definitions (§§ 606.3, 610.39, 630.3, 640.125) • C. Standard Operating Procedures (§ 606.100) • D. Control of Bacterial Contamination of Platelets (§ 606.145) • E. Records (§ 606.160) • F. Test Requirements (§§ 610.40, 640.5, 640.71(a)) • G. Donor Deferral (§ 610.41) 5 Organization of the Final Rule - 2 • H. Purpose and Scope (§ 630.1) • I. Medical Supervision (§ 630.5) • J. General Donor Eligibility Requirements(§ 630.10) • K. Donor Eligibility Requirements Specific to Whole Blood, Red Blood Cells and Plasma Collected by Apheresis (§ 630.15) • L.
    [Show full text]
  • 27. Clinical Indications for Cryoprecipitate And
    27. CLINICAL INDICATIONS FOR CRYOPRECIPITATE AND FIBRINOGEN CONCENTRATE Cryoprecipitate is indicated in the treatment of fibrinogen deficiency or dysfibrinogenaemia.1 Fibrinogen concentrate is licenced for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenaemia and hypofibrinogenaemia,2 and is currently funded under the National Blood Agreement. Key messages y Fibrinogen is an essential component of the coagulation system, due to its role in initial platelet aggregation and formation of a stable fibrin clot.3 y The decision to transfuse cryoprecipitate or fibrinogen concentrate to an individual patient should take into account the relative risks and benefits.3 y The routine use of cryoprecipitate or fibrinogen concentrate is not advised in medical or critically ill patients.2,4 y Cryoprecipitate or fibrinogen concentrate may be indicated in critical bleeding if fibrinogen levels are not maintained using FFP. In the setting of major obstetric haemorrhage, early administration of cryoprecipitate or fibrinogen concentrate may be necessary.3 Clinical implications y The routine use of cryoprecipitate or fibrinogen concentrate in medical or critically ill patients with coagulopathy is not advised. The underlying causes of coagulopathy should be identified; where transfusion is considered necessary, the risks and benefits should be considered for each patient. Specialist opinion is advised for the management of disseminated intravascular coagulopathy (MED-PP18, CC-PP7).2,4 y Cryoprecipitate or fibrinogen concentrate may be indicated in critical bleeding if fibrinogen levels are not maintained using FFP. In patients with critical bleeding requiring massive transfusion, suggested doses of blood components is 3-4g (CBMT-PP10)3 in adults or as per the local Massive Transfusion Protocol.
    [Show full text]
  • The Rare Coagulation Disorders
    Treatment OF HEMOPHILIA April 2006 · No. 39 THE RARE COAGULATION DISORDERS Paula HB Bolton-Maggs Department of Haematology Manchester Royal Infirmary Manchester, United Kingdom Published by the World Federation of Hemophilia (WFH) © World Federation of Hemophilia, 2006 The WFH encourages redistribution of its publications for educational purposes by not-for-profit hemophilia organizations. In order to obtain permission to reprint, redistribute, or translate this publication, please contact the Communications Department at the address below. This publication is accessible from the World Federation of Hemophilia’s web site at www.wfh.org. Additional copies are also available from the WFH at: World Federation of Hemophilia 1425 René Lévesque Boulevard West, Suite 1010 Montréal, Québec H3G 1T7 CANADA Tel. : (514) 875-7944 Fax : (514) 875-8916 E-mail: [email protected] Internet: www.wfh.org The Treatment of Hemophilia series is intended to provide general information on the treatment and management of hemophilia. The World Federation of Hemophilia does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. Dose schedules and other treatment regimes are continually revised and new side effects recognized. WFH makes no representation, express or implied, that drug doses or other treatment recommendations in this publication are correct. For these reasons it is strongly recommended that individuals seek the advice of a medical adviser and/or to consult printed instructions provided by the pharmaceutical company before administering any of the drugs referred to in this monograph. Statements and opinions expressed here do not necessarily represent the opinions, policies, or recommendations of the World Federation of Hemophilia, its Executive Committee, or its staff.
    [Show full text]
  • Cryosupernatant Plasma
    Cryosupernatant Plasma APPLICABILITY: This document applies to Other Names: Cryopoor Plasma AHS, Covenant Health, and all other health Class: Human blood component care professionals involved in the transfusion of blood components and products in Alberta INTRAVENOUS OTHER Intermittent Continuous ROUTES DIRECT IV SC IM OTHER Infusion Infusion Acceptable No Yes No No No N/A Routes* * Professionals performing these restricted activities have received authorization from their regulatory college and have the knowledge and skill to perform the skill competently. DESCRIPTION OF PRODUCT: . Cryosupernatant Plasma (CSP) is prepared from slowly thawed Frozen Plasma that is centrifuged to separate the insoluble cryopreciptate from the plasma. The remaining Cryosupernatant plasma is then refrozen. The approximate volume of a unit is 273 mL . CSP has reduced levels of Factor VIII and von Willebrand Factor (vWF), and does not contain measurable amounts of Factor VIII or fibrinogen. Donors are screened and blood donations are tested for: . ABO/Rh and clinically significant antibodies . Antibodies to human immunodeficiency virus (HIV-1 and HIV-2), hepatitis C virus (HCV), human T-cell lymphotropic virus type I and II (HTLV-I/II), hepatitis B core antigen (HBcore) . Hepatitis B Surface Antigen (HBsAg) . Presence of viral RNA (HIV-1 and HCV) and viral DNA (hepatitis B virus (HBV)) . Syphilis AVAILABILITY: . Not all laboratories/transfusion services stock CSP. Product is stored frozen, and as a result requires preparation time prior to issuing. Patient blood type should be determined when possible to allow for ABO specific/compatible plasma transfusion INDICATIONS FOR USE: . Plasma exchange in patients with Thrombotic Thrombocytopenic Purpura (TTP) or Hemolytic Uremic Syndrome (HUS).
    [Show full text]
  • Changes to the Technical Manual, 18Th Edition Monday, November 17, 2014 12:00 P.M
    Changes to the Technical Manual, 18th Edition Monday, November 17, 2014 12:00 p.m. – 1:30 p.m. (ET) / 5:00p.m. – 6:30 p.m. (GMT) When this file is opened, Acrobat Reader will, by default, display the slides including the Acrobat reader controls. To return to full screen mode, hit Ctrl-L on your computer keyboard or use your mouse to click View>Full Screen on the menu bar of the Acrobat Reader program. To take the slides out of full screen mode and display the Acrobat Reader controls, simply hit the Esc key on your computer keyboard. To advance slides during the program, use the Enter, Page Down, down arrow or right arrow on your computer keyboard. To back up slides during the program, use the Page Up, up arrow of left arrow on your computer keyboard. Please remember to logon to the Live Learning Center using your email address and password to complete an evaluation of the program and speakers. At this time, advance to the next slide and wait for the audioconference to begin. A 2014 Audioconference presented to you by AABB The AABB Technical Manual 18th Edition What’s new? www.aabb.org Technical Manual by the Numbers • 1953 =year of first edition • 69 = number of authors/editors this edition • 370,378 = word count • 96 = number of methods • 60 = number of countries where TM is used www.aabb.org It’s a Process www.aabb.org Overview of Changes Major • Molecular testing • Patient blood management • Cellular therapy • Methods Minor • Throughout www.aabb.org 1: Quality Systems 2: Facilities and Safety • These 2 chapters are comprehensive discussions
    [Show full text]
  • Guidelines for Transfusion and Patient Blood Management, and Discuss Relevant Transfusion Related Topics
    Guidelines for Transfusion and Community Transfusion Committee Patient Blood Management Community Transfusion Committee CHAIR: Aina Silenieks, M.D., [email protected] MEMBERS: A.Owusu-Ansah, M.D. S. Dunder, M.D. M. Furasek, M.D. D. Lester, M.D. D. Voigt, M.D. B. J. Wilson, M.D. COMMUNITY Juliana Cordero, Blood Bank Coordinator, CHI Health Nebraska Heart REPRESENTATIVES: Becky Croner, Laboratory Services Manager, CHI Health St. Elizabeth Mackenzie Gasper, Trauma Performance Improvement, Bryan Medical Center Kelly Gillaspie, Account Executive, Nebraska Community Blood Bank Mel Hanlon, Laboratory Specialist - Transfusion Medicine, Bryan Medical Center Kyle Kapple, Laboratory Quality Manager, Bryan Medical Center Lauren Kroeker, Nurse Manager, Bryan Medical Center Christina Nickel, Clinical Laboratory Director, Bryan Medical Center Rachael Saniuk, Anesthesia and Perfusion Manager, Bryan Medical Center Julie Smith, Perioperative & Anesthesia Services Director, Bryan Medical Center Elaine Thiel, Clinical Quality Improvement/Trans. Safety Officer, Bryan Med Center Kelley Thiemann, Blood Bank Lead Technologist, CHI Health St. Elizabeth Cheryl Warholoski, Director, Nebraska Operations, Nebraska Community Blood Bank Jackie Wright, Trauma Program Manager, Bryan Medical Center CONSULTANTS: Jed Gorlin, M.D., Innovative Blood Resources [email protected] Michael Kafka, M.D., LifeServe Blood Center [email protected] Alex Smith, D.O., LifeServe Blood Center [email protected] Nancy Van Buren, M.D., Innovative
    [Show full text]
  • Blood Product Modifications: Leukofiltration, Irradiation and Washing
    Blood Product Modifications: Leukofiltration, Irradiation and Washing 1. Leukocyte Reduction Definitions and Standards: o Process also known as leukoreduction, or leukofiltration o Applicable AABB Standards, 25th ed. Leukocyte-reduced RBCs At least 85% of original RBCs < 5 x 106 WBCs in 95% of units tested . Leukocyte-reduced Platelet Concentrates: At least 5.5 x 1010 platelets in 75% of units tested < 8.3 x 105 WBCs in 95% of units tested pH≥6.2 in at least 90% of units tested . Leukocyte-reduced Apheresis Platelets: At least 3.0 x 1011 platelets in 90% of units tested < 5.0 x 106 WBCs 95% of units tested pH≥6.2 in at least 90% of units tested Methods o Filter: “Fourth-generation” filters remove 99.99% WBCs o Apheresis methods: most apheresis machines have built-in leukoreduction mechanisms o Less efficient methods of reducing WBC content . Washing, deglycerolizing after thawing a frozen unit, centrifugation . These methods do not meet requirement of < 5.0 x 106 WBCs per unit of RBCs/apheresis platelets. Types of leukofiltration/leukoreduction o “Pre-storage” . Done within 24 hours of collection . May use inline filters at time of collection (apheresis) or post collection o “Pre-transfusion” leukoreduction/bedside leukoreduction . Done prior to transfusion . “Bedside” leukoreduction uses gravity-based filters at time of transfusion. Least desirable given variability in practice and absence of proficiency . Alternatively performed by transfusion service prior to issuing Benefits of leukoreduction o Prevention of alloimmunization to donor HLA antigens . Anti-HLA can mediate graft rejection and immune mediated destruction of platelets o Leukoreduced products are indicated for transplant recipients or patients who are likely platelet transfusion dependent o Prevention of febrile non-hemolytic transfusion reactions (FNHTR) .
    [Show full text]
  • Guidance for the Provision of Intraoperative Cell Salvage
    Enter Organisation details here GUIDANCE FOR THE PROVISION OF INTRAOPERATIVE CELL SALVAGE Guidance Guidance forfor Australian Australian Health Health Providers Providers MARCH> MARCH 2014 2014 Guidance for the provision of Intraoperative Cell Salvage Page 0 Ref No: Enter Organisation Ref AUS ICS Version No: 1 March 2014 Enter Organisation details here With the exception of any logos and registered trademarks, and where otherwise noted, all material presented in this document is provided under a Creative Commons Attribution 3.0 Australia (http://creativecommons.org/ licenses/by/3.0/au/) licence. The details of the relevant licence conditions are available on the Creative Commons website (accessible using the links provided) as is the full legal code for the CC BY 3.0 AU license (http://creativecommons.org/licenses/by/3.0/au/legalcode). The content obtained from this document or derivative of this work must be attributed as the Guidance for the provision of Intraoperative Cell Salvage. © National Blood Authority, 2014. ISBN 978-0-9873687-3-7 This report is available online at: www.blood.gov.au For more information: Patient Blood Management National Blood Authority Locked Bag 8430 Canberra ACT 2601 Phone: 13000 BLOOD (13 000 25663) Email: [email protected] www.blood.gov.au Guidance for the provision of Intraoperative Cell Salvage Page 1 Ref No: Enter Organisation Ref AUS ICS Version No: 1 March 2014 Enter Organisation details here Guidance for the provision of Intraoperative Cell Salvage Author: Policy ratified by: Responsible Officer: Signature Date Insert Date Classification Clinical Date Issued Area Applicable Review Date Ref No: Version No: Disclaimer When using this document please ensure that the version you are using is the current, in date version by checking on your Organisation’s database for any new versions.
    [Show full text]
  • Transfusion Guidelines Updated February, 2005
    Transfusion Guidelines Updated February, 2005 I. Whole Blood The use of whole blood is not recommended and is not available from the Blood Center. Blood components should be selected according to the patient’s needs. II. Red Blood Cells (RBCs) Transfusion must be completed within 4 hours of issue from the Blood Bank. If transfusion is not begun immediately the RBCs must be stored at 1-6° C or returned to the Blood Bank. (Storage is only allowed in preapproved areas, such as the operating room and several of the critical care areas). The effectiveness of each transfusion should be documented in the medical record. Single unit transfusions of RBCs are often effective. In adult patients, one unit of RBCs will increase the hemoglobin level by approximately 1 g/dl (hematocrit by 3%). A. Acceptable Usage 1. Acute Blood loss exceeding 30-40% of blood volume (pediatric patients - 10-15 ml/Kg) and/or not responding to appropriate volume resuscitation, and/or with ongoing blood loss. 2. Patient is normovolemic and there is evidence to support a need for increased oxygen carrying capacity by the following : a. Hypotension not corrected by adequate volume replacement alone. b. PVO2<25 torr, when SaO2 completely saturated; extraction ratio>50%, VO2<50% of baseline. c. Neonates and young infants less than 56 weeks postmenstrual age with hematocrit < 0.30 and frequent and/or severe apnea/bradycardia, poor weight gain, sustained tachycardia and/or tachypnea or mild respiratory distress. d. Neonates and young infants less than 56 weeks postmenstrual age with hematocrit < 0.35 and moderate respiratory distress or with hematocrit < 0.40 and severe respiratory distress, cyanotic congenital heart disease or receiving extracorporeal membrane oxygenation.
    [Show full text]
  • ISTH Couverture 6.6.2012 10:21 Page 1 ISTH Couverture 6.6.2012 10:21 Page 2 ISTH Couverture 6.6.2012 10:21 Page 3 ISTH Couverture 6.6.2012 10:21 Page 4
    ISTH Couverture 6.6.2012 10:21 Page 1 ISTH Couverture 6.6.2012 10:21 Page 2 ISTH Couverture 6.6.2012 10:21 Page 3 ISTH Couverture 6.6.2012 10:21 Page 4 ISTH 2012 11.6.2012 14:46 Page 1 Table of Contents 3 Welcome Message from the Meeting President 3 Welcome Message from ISTH Council Chairman 4 Welcome Message from SSC Chairman 5 Committees 7 ISTH Future Meetings Calendar 8 Meeting Sponsors 9 Awards and Grants 2012 12 General Information 20 Programme at a Glance 21 Day by Day Scientific Schedule & Programme 22 Detailed Programme Tuesday, 26 June 2012 25 Detailed Programme Wednesday, 27 June 2012 33 Detailed Programme Thursday, 28 June 2012 44 Detailed Programme Friday, 29 June 2012 56 Detailed Programme Saturday, 30 June 2012 68 Hot Topics Schedule 71 ePoster Sessions 97 Sponsor & Exhibitor Profiles 110 Exhibition Floor Plan 111 Congress Centre Floor Plan www.isth.org ISTH 2012 11.6.2012 14:46 Page 2 ISTH 2012 11.6.2012 14:46 Page 3 WelcomeCommittees Messages Message from the ISTH SSC 2012 Message from the ISTH Meeting President Chairman of Council Messages Dear Colleagues and Friends, Dear Colleagues and Friends, We warmly welcome you to the elcome It is my distinct privilege to welcome W Scientific and Standardization Com- you to Liverpool for our 2012 SSC mittee (SSC) meeting of the Inter- meeting. national Society on Thrombosis and Dr. Cheng-Hock Toh and his col- Haemostasis (ISTH) at Liverpool’s leagues have set up a great Pro- UNESCO World Heritage Centre waterfront! gramme aiming at making our off-congress year As setting standards is fundamental to all quality meeting especially attractive for our participants.
    [Show full text]
  • FDA Regulation of Blood and Blood Components in the United States
    FDA Regulation of Blood and Blood Components in the United States SLIDE 1 This presentation will review the FDA Regulation of Blood and Blood Components in the U.S. SLIDE 2 The FDA Center for Biologics Evaluation and Research, or CBER, Office of Blood Research and Review, called OBRR, reviews several different types of regulatory applications with respect to blood and blood components. This includes biologics license applications, called BLAs, which represent the regulatory pathway for blood components. The BLA regulatory process also applies to biological drugs such as fractionated plasma products. OBRR also regulates in-vitro diagnostic devices used for screening of collected blood, and does so also using the BLA regulatory pathway. Review of these devices as biologic licenses allows CBER to apply a higher level of manufacturing oversight, including lot release testing and pre-licensure inspection. This regulatory pathway applies to infectious disease tests for blood screening, as well as blood grouping and phenotyping reagents. SLIDE 3 The regulatory pathway for New Drug Applications, or NDAs, is most commonly used within the Center for Drug Evaluation and Research, or CDER. Within the Office of Blood, several NDA applications are reviewed each year, mostly involving solutions used for the collection of blood, such as anticoagulants and red cell nutritive solutions. Interestingly, a blood bag that does not have a solution inside is regulated as a device. If the bag has a solution, then it is a drug-device combination product, but is regulated as a drug. SLIDE 4 OBRR reviews both Class Two and Class Three devices. Class Three devices in OBRR include diagnostic tests for HIV regulated as pre-market approvals, called PMAs.
    [Show full text]